NCT06961006: An ongoing trial by Merck Sharp & Dohme LLC
This trial is ongoing. It must report results 3 years, 7 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06961006 |
|---|---|
| Title | A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 29, 2025 |
| Completion date | July 22, 2028 |
| Required reporting date | July 22, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |